IN THE CLAIMS:

Claim 1 (canceled).

Claim 2 (currently amended and reformatted): A **bicyclic** ~~**bicylic**~~ compound of the Formula (I): ~~**according to claim 1**~~



(I)

wherein:

G is N;

the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring within Formula (I) is furopyrimidinyl, thienopyrimidinyl, pyrrolopyrimidinyl, oxazolopyrimidinyl, thiazolopyrimidinyl, purinyl, pyridopyrimidinyl, pyrimidopyrimidinyl or pteridinyl;

m is 0 or ~~**m is**~~ 1; ~~**and each**~~

R^1 is ~~**independently**~~ hydroxy, halo, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}alkylS(O)$_n$- (wherein n is 0-2), *N*,*N*-(C_{1-6}alkyl)$_2$aminoC_{1-6}alkyl, *N*,*N*-(C_{1-6}alkyl)$_2$carbamoylC_{1-6}alkoxy, *N*,*N*-(C_{1-6}alkyl)$_2$aminoC_{1-6}alkoxy, C_{1-6}alkylS(O)$_2$-C_{1-6}alkoxy, *N*,*N*-(C_{1-6}alkyl)$_2$amino-*N*-(C_{1-6}alkyl)C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$aminoC_{1-6}alkylaminoC_{1-6}alkyl, piperidin-1-ylC_{1-6}alkyl, homopiperidin-1-ylC_{1-6}alkyl, *N*-(C_{1-6}alkyl)piperidin-1-ylC_{1-6}alkyl, *N*-(C_{1-6}alkyl) homopiperidin-1-ylC_{1-6}alkyl, piperazin-1-ylC_{1-6}alkyl, 4-C_{1-6}alkylpiperazin-1-ylC_{1-6}alkyl, homopiperazinyl-1-ylC_{1-6}alkyl, 4-C_{1-6}alkylhomopiperazinyl-1-ylC_{1-6}alkyl, pyrrolidinylC_{1-6}alkoxy, piperidinylC_{1-6}alkoxy, homopiperidinylC_{1-6}alkoxy, *N*-(C_{1-6}alkyl)pyrrolidinylC_{1-6}alkoxy, *N*-(C_{1-6}alkyl)piperidinylC_{1-6}alkoxy,

N-(C_{1-6}alkyl)homopiperidinylC_{1-6}alkoxy, morpholinylC_{1-6}alkoxy, piperazinylC_{1-6}alkoxy, *N*-(C_{1-6}alkyl)piperazinylC_{1-6}alkoxy, homopiperazinylC_{1-6}alkoxy, *N*-(C_{1-6}alkyl)homopiperazinylC_{1-6}alkoxy, pyrrolidinyloxy, *N*-(C_{1-6}alkyl)pyrrolidinyloxy, piperidinyloxy, *N*-(C_{1-6}alkyl)piperidinyloxy, homopiperidinyloxy, *N*-(C_{1-6}alkyl)homopiperidinyloxy, morpholinylC_{1-6}alkylaminoC_{1-6}alkyl, thiazolylC_{1-6}alkoxy or pyridylC_{1-6}alkoxy;

and any aryl, heteroaryl or heterocyclyl group in a R^1 group may be optionally substituted with one or more groups selected from hydroxy, halo, C_{1-6}alkyl, C_{1-6}alkoxy, carboxy, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-C_{1-6}alkylcarbamoyl, *N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{2-6}alkanoyl, amino, *N*-C_{1-6}alkylamino and *N*,*N*-(C_{1-6}alkyl)$_2$amino,

and any heterocyclyl group in a R^1 group may be optionally substituted with one or two oxo or thioxo substituents,

and any of the R^1 groups defined hereinbefore which comprises a CH_2 group which is attached to 2 carbon atoms or a CH_3 group which is attached to a carbon atom may optionally bear on each said CH_2 or CH_3 group a substituent selected from hydroxy, amino, C_{1-6}alkoxy, *N*-C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$amino and heterocyclyl;

R^2 is hydrogen, C_{1-4}alkyl or halo;

R^3 is hydrogen, C_{1-4}alkyl or halo;

q is 0;

R^4 is phenyl, thienyl, furyl, oxazolyl, isoxazolyl, pyrimidyl or pyridyl optionally substituted by one or two halo, trifluoromethyl, cyano, C_{1-4}alkyl, C_{1-4}alkoxy, -O-(C_{1-3}alkyl)-O-, *N*,*N*-(C_{1-4}alkyl)$_2$amino, C_{1-6}alkanoylamino, C_{1-6}alkylsulphonyl-*N*-(C_{1-6}alkyl)amino, phenyl (optionally substituted by one or two halo groups), furyl, azetidinyl, pyrrolidinyl, 3-pyrrolinyl, **piperidinyl** ~~**piperidino**~~, homopiperidinyl, morpholino, piperazinyl, homopiperazinyl, *N*-(C_{1-6}alkyl)piperazinyl and *N*-(C_{1-6}alkyl)homopiperazinyl, or R^4 is fluorenyl or dibenzofuranyl;

and any aryl, heteroaryl or heterocyclyl group in a R^4 group may be optionally substituted by one or more groups selected from hydroxy, halo, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy, carbamoyl, formyl, sulphamoyl, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{1-6}alkoxy, -O-(C_{1-3}alkyl)-O-, C_{1-6}alkylS(O)$_n$- (wherein n is 0-2), *N*-C_{1-6}alkylamino,

N,*N*-(C_{1-6}alkyl)$_2$amino, C_{1-6}alkoxycarbonyl, *N*-C_{1-6}alkylcarbamoyl, *N*,*N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{2-6}alkanoyl, C_{1-6}alkanoyloxy, C_{1-6}alkanoylamino, *N*-C_{1-6}alkylsulphamoyl, *N*,*N*-(C_{1-6}alkyl)$_2$sulphamoyl, C_{1-6}alkylsulphonylamino and C_{1-6}alkylsulphonyl-*N*-(C_{1-6}alkyl)amino,

or any aryl, heteroaryl or heterocyclyl group in a R^4 group may be optionally substituted with one or more groups of the Formula (IA'):

$$-B^1-(CH_2)_p-A^1 \qquad \text{(IA')}$$

wherein A^1 is halo, hydroxy, C_{1-6}alkoxy, cyano, amino, *N*-C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$amino, carboxy, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-C_{1-6}alkylcarbamoyl or *N*,*N*-(C_{1-6}alkyl)$_2$carbamoyl, p is 1 - 6, and B^1 is a bond, oxy, imino, *N*-(C_{1-6}alkyl)imino or -NHC(O)-, with the proviso that p is 2 or more unless B^1 is a bond or -NHC(O)-,

or any aryl, heteroaryl or heterocyclyl group in a R^4 group may be optionally substituted with one or more groups of the Formula (IB'):

$$-E^1-D^1 \qquad \text{(IB')}$$

wherein D^1 is aryl, heteroaryl or heterocyclyl and E^1 is a bond, C_{1-6}alkylene, oxyC_{1-6}alkylene, oxy, imino, *N*-(C_{1-6}alkyl)imino, iminoC_{1-6}alkylene, *N*-(C_{1-6}alkyl)-iminoC_{1-6}alkylene, C_{1-6}alkylene-oxyC_{1-6}alkylene, C_{1-6}alkylene-iminoC_{1-6}alkylene, C_{1-6}alkylene-*N*-(C_{1-6}alkyl)-iminoC_{1-6}alkylene, -NHC(O)-, -$NHSO_2$-, -SO_2NH- or -NHC(O)-C_{1-6}alkylene-,

and any aryl, heteroaryl or heterocyclyl group in a substituent on R^4 may be optionally substituted with one or more groups selected from hydroxy, halo, C_{1-6}alkyl, C_{1-6}alkoxy, carboxy, C_{1-6}alkoxycarbonyl, carbamoyl, *N*-C_{1-6}alkylcarbamoyl, *N*-(C_{1-6}alkyl)$_2$carbamoyl, C_{2-6}alkanoyl, amino, *N*-C_{1-6}alkylamino and *N*,*N*-(C_{1-6}alkyl)$_2$amino,

and any C_{3-7}cycloalkyl or heterocyclyl group in a R^4 group may be optionally substituted with one or two oxo or thioxo substituents,

and any of the R^4 groups defined hereinbefore which comprises a CH_2 group which is attached to 2 carbon atoms or a CH_3 group which is attached to a carbon atom may optionally bear on each said CH_2 or CH_3 group a substituent selected from hydroxy, amino, C_{1-6}alkoxy, *N*-C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$amino and heterocyclyl;

and

R^5 is hydrogen;

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 3 (currently amended): A bicyclic compound of the Formula (I) according to claim **2** ~~1~~ wherein:

~~**the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring within Formula (I) is furopyrimidinyl, thienopyrimidinyl, pyrrolopyrimidinyl, oxazolopyrimidinyl, thiazolopyrimidinyl, purinyl, pyridopyrimidinyl, pyrimidopyrimidinyl or pteridinyl;**~~

~~**m is 0 or m is 1 and each**~~ R^1 is ~~**independently**~~ hydroxy, halo, C_{1-6}alkyl, C_{1-6}alkoxy, C_{1-6}alkylS(O)$_n$- (wherein n is 0-2), *N*,*N*-(C_{1-6}alkyl)$_2$aminoC_{1-6}alkyl, *N*,*N*-(C_{1-6}alkyl)$_2$carbamoylC_{1-6}alkoxy, *N*,*N*-(C_{1-6}alkyl)$_2$aminoC_{1-6}alkoxy, C_{1-6}alkylS(O)$_2$-C_{1-6}alkoxy, *N*,*N*-(C_{1-6}alkyl)$_2$amino-*N*-(C_{1-6}alkyl)C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$aminoC_{1-6}alkylaminoC_{1-6}alkyl, piperazin-1-ylC_{1-6}alkyl, 4-C_{1-6}alkylpiperazin-1-ylC_{1-6}alkyl, homopiperazinyl-1-ylC_{1-6}alkyl, 4-C_{1-6}alkylhomopiperazinyl-1-ylC_{1-6}alkyl, pyrrolidinylC_{1-6}alkoxy, piperidinylC_{1-6}alkoxy, *N*-(C_{1-6}alkyl)pyrrolidinylC_{1-6}alkoxy, *N*-(C_{1-6}alkyl)piperidinylC_{1-6}alkoxy,morpholinylC_{1-6}alkoxy, piperazinylC_{1-6}alkoxy, *N*-(C_{1-6}alkyl)piperazinylC_{1-6}alkoxy, homopiperazinylC_{1-6}alkoxy, *N*-(C_{1-6}alkyl)homopiperazinylC_{1-6}alkoxy, pyrrolidinyloxy, piperidinyloxy, morpholinylC_{1-6}alkylaminoC_{1-6}alkyl or pyridylC_{1-6}alkoxy; **and**

~~**R^2 is hydrogen, C_{1-4}alkyl or halo;**~~

~~**R^3 is hydrogen, C_{1-4}alkyl or halo;**~~

~~**q is 0;**~~

R^4 is phenyl, thienyl, furyl, oxazolyl, isoxazolyl, pyrimidyl or pyridyl optionally substituted by one or two halo, cyano, C_{1-4}alkyl, C_{1-4}alkoxy, *N*,*N*-(C_{1-4}alkyl)$_2$amino, piperidinyl, morpholino or piperazinyl; ~~**and**~~

~~**R^5 is hydrogen;**~~

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 4 (currently amended): A bicyclic compound of the Formula (I) according to claim **2** ~~1~~ wherein:

the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring within Formula (I) is furo[3,2-*d*]pyrimidinyl, furo[2,3-*d*]pyrimidinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, pyrrolo[3,2-*d*]pyrimidinyl, pyrrolo[2,3-*d*]pyrimidinyl, oxazolo[5,4-*d*]pyrimidinyl, oxazolo[4,5-*d*]pyrimidinyl, thiazolo[5,4-*d*]pyrimidinyl, thiazolo[4,5-*d*]pyrimidinyl, purinyl, pyrido[2,3-*d*]pyrimidinyl, pyrido[3,4-*d*]pyrimidinyl, pyrido[4,3-*d*]pyrimidinyl, pyrido[3,2-*d*]pyrimidinyl, pyrimido[4,5-*d*]pyrimidinyl, pyrimido[5,6-*d*]pyrimidinyl or pteridinyl;

~~m is 0 or m is 1 and each~~ R^1 is ~~independently~~ methyl, methoxy, methylthio, 2-diisopropylaminoethoxy, 3-diethylaminopropoxy, 3-morpholinopropoxy or 3-pyrrolidin-1-ylpropoxy;

R^2 is hydrogen, methyl, fluoro or chloro;

R^3 is hydrogen; **and**

~~q is 0;~~

R^4 is phenyl optionally substituted by one or two groups selected from fluoro, chloro, trifluoromethyl, cyano, methyl, methoxy, ethoxy, methylenedioxy, *N*,*N*-dimethylamino, acetamido, *N*-methylmethanesulphonamido, phenyl, 4-fluorophenyl, 4-chlorophenyl, 2-furyl, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, piperidino, homopiperidin-1-yl, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4-methylpiperazin-1-yl and 4-methylhomopiperazin-1-yl,

or R^4 is pyridyl optionally substituted by a *N*,*N*-dimethylamino, *N*,*N*-diethylamino, azetidin-1-yl, pyrrolidin-1-yl, 3-pyrrolin-1-yl, piperidino, homopiperidin-1-yl, morpholino, piperazin-1-yl, homopiperazin-1-yl, 4-methylpiperazin-1-yl or 4-methylhomopiperazin-1-yl group, or R^4 is 1-fluorenyl or dibenzofuran-4-yl; ~~and~~

~~R^5 is hydrogen;~~

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 5 (currently amended): A bicyclic compound of the Formula (I) according to claim **2** ~~1~~ wherein:

the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring within Formula (I) is furo[3,2-*d*]pyrimidinyl, furo[2,3-*d*]pyrimidinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, pyrrolo[3,2-*d*]pyrimidinyl, pyrrolo[2,3-*d*]pyrimidinyl, oxazolo[5,4-*d*]pyrimidinyl, oxazolo[4,5-*d*]pyrimidinyl, thiazolo[5,4-*d*]pyrimidinyl, thiazolo[4,5-*d*]pyrimidinyl, purinyl, pyrido[2,3-*d*]pyrimidinyl, pyrido[3,4-*d*]pyrimidinyl, pyrido[4,3-*d*]pyrimidinyl, pyrido[3,2-*d*]pyrimidinyl, pyrimido[4,5-*d*]pyrimidinyl, pyrimido[5,6-*d*]pyrimidinyl or pteridinyl;

~~m is 0 or m is 1 and each~~ R^1 is ~~independently~~ methyl, methoxy, methylthio, 2-diisopropylaminoethoxy, 3-diethylaminopropoxy, 3-morpholinopropoxy or 3-pyrrolidin-1-ylpropoxy;

R^2 is hydrogen, methyl, fluoro or chloro;

R^3 is hydrogen; **and**

~~q is 0;~~

R^4 is pyridyl optionally substituted by a *N*,*N*-dimethylamino, *N*,*N*-diethylamino, pyrrolidin-1-yl, piperidino or morpholino group; ~~and~~

~~R^5 is hydrogen;~~

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 6 (currently amended): A bicyclic compound of the Formula (I) according to **claim 2** ~~Claim 1~~ wherein:

the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring within Formula (I) is thieno[3,2-*d*]pyrimidin-4-yl, thieno[2,3-*d*]pyrimidin-4-yl, thiazolo[5,4-*d*]pyrimidin-7-yl, 6-purinyl, pyrido[2,3-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl, pyrido[3,2-*d*]pyrimidin-4-yl or pteridin-4-yl;

~~m is 0 or m is 1 and~~ R^1 is methyl or methylthio;

R^2 is methyl;

R^3 is hydrogen; **and**

~~**q is 0;**~~

R^4 is phenyl, 3-fluorophenyl, 4-cyanophenyl, 2-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-ethoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 3-(*N*,*N*-dimethylamino)phenyl, 3-acetamidophenyl, 3-(4-fluorophenyl)phenyl, 3-(2-furyl)phenyl, 3-pyrrolidin-1-ylphenyl, 3-morpholinophenyl, 3-fluoro-5-pyrrolidin-1-ylphenyl, 3-fluoro-5-piperidinophenyl, 3-fluoro-5-morpholinophenyl or 3-morpholino-5-trifluoromethylphenyl, or R^4 is 2-morpholinopyrid-4-yl, or R^4 is 1-fluorenyl or dibenzofuran-4-yl; ~~**and**~~

~~**R^5 is hydrogen;**~~

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 7 (currently amended): A bicyclic compound of the Formula (I) according to claim **2** ~~**1**~~ wherein:

the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring within Formula (I) is thieno[3,2-*d*]pyrimidin-4-yl, thieno[2,3-*d*]pyrimidin-4-yl, thiazolo[5,4-*d*]pyrimidin-7-yl, pyrido[2,3-*d*]pyrimidin-4-yl, pyrido[3,4-*d*]pyrimidin-4-yl, pyrido[4,3-*d*]pyrimidin-4-yl, pyrido[3,2-*d*]pyrimidin-4-yl or pteridin-4-yl;

~~**m is 0 or m is 1 and**~~ R^1 is methyl or methylthio;

R^2 is methyl;

R^3 is hydrogen; **and**

~~**q is 0;**~~

R^4 is 2-morpholinopyrid-4-yl; ~~**and**~~

~~**R^5 is hydrogen;**~~

or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 8 (currently amended): A bicyclic compound of the Formula (I) according to claim **2** ~~**1**~~ selected from:

4-[2-methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]thieno[3,2-*d*]pyrimidine,

4-[2-methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]pyrido[4,3-*d*]pyrimidine,
4-[2-methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]pteridine and
6-[2-methyl-5-(2-morpholinopyridine-4-carboxamido)anilino]purine;
or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof.

Claim 9 (currently amended): A process for preparing a compound of the Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to claim **2** ~~1~~ which comprises:

a) reacting an aniline of the Formula (II):



(II)

with an acyl compound of the Formula (III):



(III)

wherein G, R^1, R^2, R^3, R^4, R^5, **m, q and the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring** ~~ring x, m and q~~ are as defined in claim **2** ~~1~~ and L is a displaceable group;

b) reacting an activated bicyclic heteroaryl ring of the Formula (IV):



(IV)

wherein G, R^1, ~~ring X and~~ m **and the bicyclic ring formed by the fusion of ring X to the adjacent nitrogen-containing 6-membered heteroaryl ring** are as defined in claim **2** ~~1~~ and wherein L is a displaceable group, with an aniline of the Formula (V):



(V)

wherein R^2, R^3, R^4, R^5 and q are as defined in claim **2** ~~1~~; or

c) for the preparation of a compound of the Formula (I) wherein R^1 or a substituent on R^4 is C_{1-6}alkoxy or substituted C_{1-6}alkoxy, C_{1-6}alkylS-, *N*-C_{1-6}alkylamino, *N*,*N*-(C_{1-6}alkyl)$_2$amino ~~or substituted C_{1-6}alkylamino~~, the alkylation, conveniently in the presence of a suitable base, of a compound of the Formula (I) wherein R^1 or a substituent on R^4 is hydroxy, mercapto or amino as appropriate;

and thereafter if necessary:

i) converting a compound of the Formula (I) into another compound of the Formula (I);

ii) removing any protecting groups; and

iii) forming a pharmaceutically acceptable salt or *in vivo* cleavable ester.

Claim 10. (currently amended): A pharmaceutical composition which comprises a bicyclic compound of the Formula (I), or a pharmaceutically acceptable salt or *in vivo* cleavable ester thereof, according to any one of claims **2-8** ~~1-8~~ in association with a pharmaceutically acceptable diluent or carrier.

Claim 11 (canceled).

Claim 12 (currently amended): A method of treating a disease or medical condition mediated by cytokines which comprises administering to a warm-blooded animal in need thereof an effective amount of a bicyclic compound of the Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to any one of claims **2-8** ~~1-8~~.

Claim 13 (canceled).

Claim 14 (new): A method for producing an enzyme p38 kinase inhibiting effect in a warm-blooded animal which comprises administering to said animal an enzyme inhibiting amount of a compound of Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to any one of claims 2-8.

Claim 15 (new): A method for producing a TNFα inhibiting effect in a warm-blooded animal which comprises administering to said animal a TNFα inhibiting amount of a compound of Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to any one of claims 2-8.

Claim 16 (new): A method for the treatment of rheumatoid arthritis in a warm-blooded animal in need thereof comprising administering to said animal a treatment-effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or an *in vivo* cleavable ester thereof, according to any one of claims 2-8.

Claim 17 (new): A method for producing an enzyme p38 kinase inhibiting effect in a warm-blooded animal which comprises administering to said animal an enzyme inhibiting amount of the compound 7-amino-4-(3-acetamidoanilino)pyrido[4,3-*d*]pyrimidine.

Claim 18 (new): A method for producing TNFα inhibiting effect in a warm-blooded animal which comprises administering to said animal TNFα inhibiting amount of the compound 7-amino-4-(3-acetamidoanilino)pyrido[4,3-*d*]pyrimidine.

Claim 19 (new): A method for the treatment of rheumatoid arthritis in a warm-blooded animal in need thereof comprising administering to said animal a treatment-effective amount of the compound 7-amino-4-(3-acetamidoanilino)pyrido[4,3-*d*]pyrimidine.